WebDAPHNe: De-escalation to adjuvant antibodies post-pCR to neoadjuvant THP (paclitaxel/trastuzumab/pertuzumab)-a pilot study in HER2-positive breast cancer Not … WebApr 5, 2024 · Finally, the DAPHNE clinical trial, presented at the last San Antonio Breast Cancer Meeting in 2024, demonstrated that a de-escalation of the amount of chemotherapy is feasible in patients with stage 2 or 3 treated with neoadjuvant paclitaxel, trastuzumab, and pertuzumab who achieve a pathological complete response at the surgery.
Comparison of Axillary Lymph Node Dissection With Axillary …
WebAbstract PD3-05: The DAPHNE trial: A feasibility study of chemotherapy de-escalation based on response to neoadjuvant paclitaxel-HP (THP) in HER2-positive breast cancer. … WebFeb 12, 2024 · The main purpose of this study is to measure how well abemaciclib works in participants with early breast cancer who are taking hormone therapy after surgery. Participants must have breast cancer that is hormone receptor positive (HR+) and human epidermal receptor 2 positive (HER2+). porsche sprint challenge middle east facebook
Altmetric – Abstract PD3-05: The DAPHNE trial: A …
WebJul 17, 2013 · This randomized phase III trial studies lymph node dissection and radiation therapy to see how well it works compared to radiation therapy alone in treating patients with breast cancer previously treated with chemotherapy and surgery. Lymph node dissection may remove cancer cells that have spread to nearby lymph nodes in patients with breast ... WebMar 9, 2024 · Fifteen years of studies since the approval of adjuvant trastuzumab have led to effective and more tolerable treatment regimens for patients with HER2-positive breast cancer. Patients today with small, … WebResponse Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer: The … irish dishes with cabbage